South San Francisco-based Tenaya Therapeutics Inc, a provider of curative therapies that target the underlying causes of heart disease, has secured $92 million in Series B financing. Casdin Capital led the round with participation from other investors that included GV and The Column Group.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.